Cancer Institute A national cancer institute
designated cancer center
Email this profile
Portrait View Larger

Branimir I. Sikic, M. D.

Academic Appointments

  • Professor of Medicine (Oncology)

Key Documents

Contact Information

  • Clinical Offices
    Medical Oncology 875 Blake Wilbur Dr Clinic E MC 5820 Stanford, CA 94305
    Tel Work (650) 498-6000 Fax (650) 725-9113
  • Academic Offices
    Personal Information
    Email Tel (650) 725-6427
    Alternate Contact
    Carla Edwards Administrative Assistant Tel Work 650-723-5290
    Not for medical emergencies or patient use

Professional Overview


Branimir I. (Brandy) Sikic, M. D., is Professor of Medicine in the Division of Oncology at Stanford University School of Medicine. He is Co-director of the Stanford University Center for Clinical and Translational Education and Research (Spectrum) and Director of the Stanford Clinical and Translational Research Unit (CTRU). He received his undergraduate education at Georgetown University, and an M. D. from the University of Chicago. He returned to Georgetown for his residency in internal medicine, and performed a research fellowship in cancer pharmacology at the National Cancer Institute and in medical oncology at Georgetown prior to his appointment to the Stanford University faculty in 1979. He has authored more than 230 publications, edited two books, and is the inventor of two U.S. patents. He has served on several advisory committees of the National Institutes of Health, including as chairman of the Experimental Therapeutics I Study Section. In 2005-6 he chaired the Scientific Program Committee for the American Society of Clinical Oncology (ASCO), and in 2008-9 was co-chair of the Program Committee of the American Association for Cancer Research (AACR). In 2010 he was awarded the Katarina Zrinska medal for science and medicine by the president of Croatia. Dr. Sikic is a leader in the pharmacology of anticancer drugs and the development of new cancer therapies. His research spans the spectrum from molecular and genetic approaches in cancer cells to clinical trials in cancer patients. Dr. Sikic's laboratory studies mechanisms of drug resistance in cancer cells and the development of more effective cancer therapies. He has made major contributions to understanding the problem of multidrug resistance in cancer cells. Current molecular and genetic studies of drug resistance in cellular and murine models include epithelial to mesenchymal transition (EMT), tubulin dynamicity, IAP inhibitors, and the CCLS/CCR2 pathway. Active clinical trials of new anticancer drugs include kinase inhibitors, and antibodies activating the T-cell regulating CD27 pathway and the macrophage regulating CD47 pathway.

Clinical Focus

  • Cancer> Sarcoma
  • Medical Oncology
  • New Drug Studies

Administrative Appointments

  • Co-Director, Stanford Center for Clinical and Translational Education and Research, Stanford University (2008 - present)
  • Director, Clinical and Translational Research Unit, Stanford University (2008 - present)
  • Scientific Program Committee Chair, American Society of Clinical Oncology (2005 - 2006)

Honors and Awards

  • Presidential Medal for Science and Medicine, Government of Croatia (2010)
  • Statesman Award, American Society of Clinical Oncology (2010)
  • John H. Blaffer Visiting Professor, M.D. Anderson Cancer Center (2003)
  • Best Doctors in America, "Best Doctors" annual survey (2002-13)
  • Oncology Teaching Award, Oncology Division, Stanford (2000)
  • Plenary lecturer in drug resistanc e, Netherlands Cancer Institute (1999)
View All 8honors and awards of Branimir Sikic

Professional Education

Fellowship: Georgetown University Hospital DC (1979)
Residency: Georgetown University Hospital DC (1975)
Board Recertification: Medical Oncology, American Board of Internal Medicine (2010)
Board Certification: Medical Oncology, American Board of Internal Medicine (1979)
Fellowship: National Cancer Institute MD (1978)
Board Certification: Internal Medicine, American Board of Internal Medicine (1975)
View All 10

Community and International Work



Postdoctoral Advisees

Rishil Kathawala

Graduate and Fellowship Program Affiliations

Scientific Focus

Current Research and Scholarly Interests

Our goals are to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I, II and III clinical trials of new inhibitors of drug resistance and novel therapies such as multi-targeted tyrosine kinase inhibitors and activators of TRAIL signaling. We are developing approaches to personalized therapies of ovarian cancer using biomarkers to select individualized treatments for patients.

Laboratory projects include studies of the multidrug transporter P-glycoprotein, regulation of the MDR1 gene, the role of beta tubulin gene expression in resistance to taxanes and vinca alkaloids, and the use of gene expression profiling in discovering molecular and genetic determinants of outcomes in cancer treatment in various cancers, particularly ovarian, colorectal, and acute myeloid leukemias.

Clinical investigations include the prognostic significance of resistance gene expression in cancers, pharmacokinetic consequences of MDR modulation, development of new modulators of drug resistance, and new targeted drugs, including kinase inhibitors and inhibitors of apoptosis. We are performing pharmacogenetic and pharmacogenomic studies to investigate determinants of response and toxicities in these patients.


Publication tag cloud

Publication Topics

View All 195

Stanford Medicine Resources:

Footer Links: